Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Fluxome capital

This article was originally published in The Tan Sheet

Executive Summary

Copenhagen-based biotechnology firm Fluxome Sciences secured 100 million Danish krone ($21.3 million under the July 23 conversion rates) in its latest round of financing, the firm announces July 23. Claude J. Stoufs, senior investment manager for Fluxome shareholder Capricorn Venture Partners, says he anticipates the latest capital increase will help Fluxome "become a major player in the field of nutraceutical ingredients based on production by engineered microorganisms." In June, Fluxome announced a partnership with CP Kelco U.S., a division of J.M. Huber, to develop and commercialize fermentation-derived resveratrol for the dietary supplement market, tentatively aiming for a product launch this fall...

You may also be interested in...



Colgate Was Drawn To Hello Products’ Youthful Lifestyle Branding; Now It Just Launched A CBD Line

Successfully acquired by Colgate-Palmolive on 31 January, Hello quickly made a statement with the launch of a CBD oral-care range and its first go at lip care, CBD Vegan Lip Balm. Available exclusively through Ulta Beauty, the CBD products have the potential to score well with younger consumers interested in natural ingredients, eco-friendly packaging and, of course, cannabis-based innovations.

Bluebird Expects Three Filings In 2020, But US Zynteglo Submission Pushed Back

A BLA filing for Zynteglo in beta-thalassemia is expected in the second half of 2020 instead of the first half, but the first commercial patient in the EU will be treated in the first half of this year.

Balancing Act: China Approves Antiviral For Coronavirus While Promoting Traditional Medicines

Amid the ongoing spread of the coronavirus outbreak, China turns to novel and repurposed antiviral drugs but also courts traditional medicines to ease public fear over the largely unknown threat.

Topics

UsernamePublicRestriction

Register

PS101945

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel